Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Shares Shorted: Short Interest Down 58.9% in October

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) saw a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 27,571 shares, a decline of 58.9% from the October 15th total of 67,048 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average trading volume of 189,130 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Evaxion A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EVAX. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Evaxion A/S during the 1st quarter worth about $112,000. Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S in the first quarter valued at about $146,000. Finally, Rathbones Group PLC acquired a new position in Evaxion A/S in the 1st quarter worth approximately $170,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analyst Upgrades and Downgrades

EVAX has been the subject of a number of research reports. Wall Street Zen upgraded Evaxion A/S to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Evaxion A/S has an average rating of “Moderate Buy” and an average target price of $11.25.

Check Out Our Latest Report on Evaxion A/S

Evaxion A/S Stock Up 1.1%

NASDAQ EVAX traded up $0.03 on Monday, hitting $2.77. The stock had a trading volume of 27,117 shares, compared to its average volume of 95,133. The business’s fifty day moving average price is $3.13 and its 200 day moving average price is $3.43. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. Evaxion A/S has a 52-week low of $2.65 and a 52-week high of $6.92. The stock has a market cap of $24.99 million, a price-to-earnings ratio of -2.29 and a beta of 0.60.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

See Also

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.